Insider Selling: Twist Bioscience (NASDAQ:TWST) SVP Sells $48,654.06 in Stock

Twist Bioscience Corporation (NASDAQ:TWST) SVP Paula Green sold 294 shares of the firm’s stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $165.49, for a total value of $48,654.06. Following the completion of the transaction, the senior vice president directly owned 116,720 shares in the company, valued at $19,315,992.80. This trade represents a 0.25% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Twist Bioscience Trading Down 0.7%

Shares of NASDAQ:TWST opened at $182.83 on Friday. The stock has a 50 day moving average of $126.89 and a 200 day moving average of $87.13. The company has a market cap of $11.47 billion, a PE ratio of -82.36 and a beta of 2.22. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 12-month low of $23.30 and a 12-month high of $186.20.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.05). Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The firm had revenue of $118.38 million during the quarter, compared to analysts’ expectations of $114.55 million. During the same period in the prior year, the company posted $0.33 earnings per share. The company’s revenue was up 23.2% compared to the same quarter last year. As a group, equities research analysts expect that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Institutional Trading of Twist Bioscience

Institutional investors have recently bought and sold shares of the stock. Allworth Financial LP purchased a new position in Twist Bioscience during the second quarter worth $62,000. Trifecta Capital Advisors LLC purchased a new stake in shares of Twist Bioscience in the second quarter valued at $63,000. Western Wealth Management LLC purchased a new stake in shares of Twist Bioscience in the first quarter valued at $31,000. Strs Ohio bought a new stake in shares of Twist Bioscience in the 1st quarter worth about $33,000. Finally, GAMMA Investing LLC lifted its holdings in shares of Twist Bioscience by 24.4% in the 2nd quarter. GAMMA Investing LLC now owns 943 shares of the company’s stock worth $97,000 after acquiring an additional 185 shares during the last quarter.

Analyst Ratings Changes

TWST has been the topic of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a report on Monday. TD Cowen reiterated a “buy” rating on shares of Twist Bioscience in a research note on Monday, August 3rd. Robert W. Baird raised their price objective on Twist Bioscience from $113.00 to $115.00 and gave the company an “outperform” rating in a research report on Tuesday, August 4th. Piper Sandler boosted their target price on Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 5th. Finally, UBS Group started coverage on Twist Bioscience in a research note on Wednesday, September 9th. They set a “neutral” rating and a $144.00 price target for the company. Eight equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $103.00.

About Twist Bioscience

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA using a proprietary silicon-based platform. The company serves researchers and organizations in biotechnology, pharmaceutical development, agriculture, industrial chemicals and academic research.

Its products include synthetic genes, gene fragments, oligonucleotides and DNA libraries used in research, drug discovery, diagnostics development and other applications. Twist also provides next-generation sequencing tools and products, including target-enrichment and sample-preparation solutions, as well as synthetic biology services that support the design and testing of biological systems.

Twist was founded in 2013 and is headquartered in South San Francisco, California.